At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 19 enrolled
Drug / intervention
Eltrombopag oral tabletsdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Clinical Evaluation of Eltrombopag in Chronic Idiopathic Thrombocytopenic Purpura (ITP)-An Extension Study of Eltrombopag in Subjects, With Idiopathic Thrombocytopenic Purpura (ITP), Previously Enrolled in an Eltrombopag Study TRA108109 (NCT00540423)-<Phase III Study>
In Brief
A Phase 3 clinical trial evaluating Eltrombopag oral tablets for Idiopathic Thrombocytopenic Purpura and Purpura, Thrombocytopenic, Idiopathic. Completed, enrolled 19 participants across 6 sites.
Detailed Summary
An open-label, dose-adjustment extension study to evaluate the safety and efficacy of eltrombopag for treatment of subjects with ITP who have previously been enrolled in the eltrombopag trial TRA108109 (NCT00540423).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesJapan
Collaborators--
Timeline
Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMay 2008
First PostedJan 2009
Primary CompletionFeb 2011
TodayJul 2026
First PostedJan 26, 2009
Enrollment StartMay 1, 2008
Primary CompletionFeb 1, 2011
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 17.4 years ago
Interventions
Eltrombopag oral tabletsdrug
Eltrombopag oral tablets once daily